Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Rating of “Buy” by Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $85.67.

A number of research firms recently commented on GPCR. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Finally, HC Wainwright began coverage on shares of Structure Therapeutics in a research report on Wednesday, December 4th. They issued a “buy” rating and a $80.00 price target on the stock.

Structure Therapeutics Stock Performance

GPCR opened at $31.25 on Friday. The company has a fifty day moving average price of $36.32 and a two-hundred day moving average price of $39.19. The firm has a market capitalization of $1.79 billion, a PE ratio of -42.23 and a beta of -3.41. Structure Therapeutics has a 52 week low of $26.61 and a 52 week high of $62.74.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics during the second quarter worth $39,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. Quarry LP acquired a new position in Structure Therapeutics in the 2nd quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics in the 3rd quarter valued at about $202,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.